Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies.

There is a major need in target validation and therapeutic applications for molecules that can interfere with protein function inside cells. Intracellular antibodies (intrabodies) can bind to specific targets in cells but isolation of intrabodies is currently difficult. Intrabodies are normally single chain Fv fragments comprising variable domains of the immunoglobulin heavy (VH) and light chains (VL). We now demonstrate that single VH domains have excellent intracellular properties of solubility, stability and expression within the cells of higher organisms and can exhibit specific antigen recognition in vivo. We have used this intracellular single variable domain (IDab) format, based on a previously characterised intrabody consensus scaffold, to generate diverse intrabody libraries for direct in vivo screening. IDabs were isolated using two distinct antigens and affinities of isolated IDabs ranged between 20 nM and 200 nM. Moreover, IDabs selected for binding to the RAS protein could inhibit RAS-dependent oncogenic transformation of NIH3T3 cells. The IDab format is therefore ideal for in vivo intrabody use. This approach to intrabodies obviates the need for phage antibody libraries, avoids the requirement for production of antigen in vitro and allows for direct selection of intrabodies in vivo.

[1]  F. Collins,et al.  New goals for the U.S. Human Genome Project: 1998-2003. , 1998, Science.

[2]  A. Plückthun,et al.  Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. , 1998, Biochemistry.

[3]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database: a high-quality information system for comparative immunogenetics and immunology. , 2002, Developmental and comparative immunology.

[4]  T. Rabbitts,et al.  Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.

[5]  L. Riechmann,et al.  Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. , 1996, Protein engineering.

[6]  K. Wood,et al.  Firefly luciferase gene: structure and expression in mammalian cells , 1987, Molecular and cellular biology.

[7]  Thomas Tuschl,et al.  Expanding small RNA interference , 2002, Nature Biotechnology.

[8]  T. Rabbitts,et al.  Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. , 2002, Journal of molecular biology.

[9]  T. Rabbitts,et al.  Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Schuck,et al.  An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. , 1999, Journal of molecular biology.

[11]  T. Rabbitts,et al.  De novo production of diverse intracellular antibody libraries. , 2003, Nucleic acids research.

[12]  I. Pastan,et al.  Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  R. Sternglanz,et al.  Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system , 1995, Molecular and cellular biology.

[14]  E. Fearon,et al.  Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  I. Sadowski,et al.  GAL4 fusion vectors for expression in yeast or mammalian cells. , 1992, Gene.

[16]  P. Budworth,et al.  In vivo selection of single-chain antibodies using a yeast two-hybrid system. , 2000, Journal of immunological methods.

[17]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[18]  Mathieu Rouard,et al.  IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. , 2005, Developmental and comparative immunology.

[19]  L. Riechmann,et al.  Antibody VH Domains as Small Recognition Units , 1995, Bio/Technology.

[20]  L. Wyns,et al.  Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. , 2001, Trends in biochemical sciences.

[21]  A. Plückthun,et al.  Antibody scFv fragments without disulfide bonds made by molecular evolution. , 1998, Journal of molecular biology.

[22]  A. Cattaneo,et al.  Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes. , 1993, Biochemical and biophysical research communications.

[23]  R. Glockshuber,et al.  A comparison of strategies to stabilize immunoglobulin Fv-fragments. , 1990, Biochemistry.

[24]  W. Marasco,et al.  Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. , 1997, Annual review of microbiology.

[25]  Gérard Lefranc,et al.  The Immunoglobulin FactsBook , 2001 .

[26]  S. Muyldermans,et al.  Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. , 1994, Protein engineering.

[27]  A. Cattaneo,et al.  Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack , 1993, Nature.

[28]  P. Martineau,et al.  Expression of an antibody fragment at high levels in the bacterial cytoplasm. , 1998, Journal of molecular biology.

[29]  P. Trail,et al.  Monoclonal antibody drug conjugates in the treatment of cancer. , 1999, Current opinion in immunology.

[30]  S. Muyldermans,et al.  Single domain antibodies: comparison of camel VH and camelised human VH domains. , 1999, Journal of immunological methods.

[31]  H R Hoogenboom,et al.  By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. , 1992, Journal of molecular biology.

[32]  C. Cepko,et al.  Construction and applications of a highly transmissible murine retrovirus shuttle vector , 1984, Cell.

[33]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Cattaneo,et al.  The selection of intracellular antibodies. , 1998, Trends in biotechnology.

[35]  K. Isselbacher,et al.  A green fluorescent protein-reporter mammalian two-hybrid system with extrachromosomal maintenance of a prey expression plasmid: application to interaction screening. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Maritan,et al.  The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. , 2002, Journal of molecular biology.

[37]  T. Rabbitts,et al.  Selection of antibodies for intracellular function using a two-hybrid in vivo system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Weiner Bispecific antibodies in cancer therapy. , 1999, Cancer journal.

[39]  T. Rabbitts,et al.  Isolation of antigen-specific intracellular antibody fragments as single chain Fv for use in mammalian cells. , 2002, Methods in molecular biology.

[40]  P. T. Jones,et al.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.

[41]  T. Rabbitts,et al.  Chromosomal translocation products engender new intracellular therapeutic technologies , 2003, Nature Medicine.

[42]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .